ReviewFrontiers in microbiology2025
Progress in the classification, optimization, activity, and application of antimicrobial peptides.
Review in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Nano-antimicrobial peptides (Nano-AMPs) to combat resistant gram-negative bacteria.Drug delivery and translational research · 2026Review
- Antimicrobial Strategies in the Era of Resistance: It Is Too Early to Give Up Antibiotic Therapy.International journal of molecular sciences · 2026Review
- Antimicrobial Peptides as Eco-Innovative Therapeutics to Overcome Antifungal Pressure-Induced Resistance in Candida Infections.Current microbiology · 2026Review
- Article
- Topical strategies for antimicrobial delivery of peptide medicines for the management of chronic wounds.Discover nano · 2026Review
- Role of antimicrobial peptide-based biomaterials in respiratory tract infections control.BMC microbiology · 2026Review
- Engineering host‑defense peptides enhanced by artificial intelligence and nano delivery systems to overcome biofilms and antimicrobial resistance.Engineering microbiology · 2026Review
- Cell-based drug delivery for combating bacteria: focus on refractory infections.Journal of nanobiotechnology · 2026Review
- Novel Hybrid Peptide ML-2 with Antibacterial and Antibiofilm Activity Against Pseudomonas aeruginosa.Current microbiology · 2026Article
- Frog Skin Peptides: Nature's Dual-Action Weapons Against Infection and Cancer.Antibiotics (Basel, Switzerland) · 2026Review
- PecbloodinApplied and environmental microbiology · 2026Article
- Ultrasound-activated MoS₂@Fe₃O₄ nanoplatform orchestrates biofilm disruption and immune reprogramming in implant-associated infections.Journal of nanobiotechnology · 2026Article
- Antimicrobial activity of a decapeptide againstMicrobiology spectrum · 2026Article
- Animal Venom Pharmacological Resources: Exploiting Bioactive Peptides to Target Multi-Drug-Resistant Bacteria.Biochemistry research international · 2026Review
- Genes and physiological strategies in bacterial antibiotic resistance.Frontiers in microbiology · 2026Review
- Marine Antimicrobial Peptides: Advances in Discovery, Multifunctional Mechanisms, and Therapeutic Translation Challenges.Marine drugs · 2025Review
- The rise of ultrashort cationic β-peptides as promising antimicrobial therapeutics.RSC medicinal chemistry · 2025Review
- Structure-Function Insights into Frog Skin Peptides Reveal Potent Inhibition of West Nile Virus Entry.International journal of molecular sciences · 2025Article
- Advances of Peptides for Plant Immunity.Plants (Basel, Switzerland) · 2025Review
- Unveiling the potential of antimicrobial peptides to combat Mycobacterium tuberculosis.Archives of microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial peptides (AMPs) come from various sources and exhibit unique antimicrobial properties. Their rapid action, effectiveness, and resistance to resistance development make them promising alternatives to combat antibiotic resistance. In addition to its excellent antibacterial properties, AMPs have superior immunomodulatory, antitumor, and antiviral activities. In recent years, the demand for AMPs has continued to increase in many fields, especially in the medical field, and the prospects are extensive. However, AMPs have the disadvantages of expensive development cost, higher hemolysis, short half-life, susceptibility to degradation by protein hydrolases, low bioavailability, toxic side effects, and other disadvantages, which seriously limit the wide application of AMPs. Therefore, fewer AMPs have been approved for marketing or are undergoing clinical trials. The review covers the period from 2001 to 2025 and provides a detailed discussion by searching databases such as Google Scholar and Web of Science. This paper reviews the progress of research on AMPs sources, structures, optimization strategies, biological activities, mechanisms of action, and applications. In general, the development approaches and the number of new AMPs have increased significantly. The improvement technologies for AMPs high hemolysis, poor stability, low bioavailability and high cost have increased significantly. The development cost of AMPs is still high, but many AMPs have been widely used in clinical, food, livestock, poultry, cosmetics and other fields. This article focuses on the commonly used optimization strategies and main activities of AMPs, aiming to effectively respond to challenges and provide a theoretical basis for expanding their application range.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.